AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
ASX rare earths play looks to expand production
The largest rare-earth producer outside of China acquires competitor to increase production.
stocks
Anthropic’s leaked financials reflect fast growth, but not a $2 trillion valuation
Draft IPO filing shows a company growing faster than its annual results can capture.
stocks
The 10 best US companies to invest in now
The stocks of these high-quality companies look cheap today.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.70 | 60.50 | 0.68% |
| CAC 40 | 7,834.10 | 63.09 | -0.80% |
| DAX 40 | 25,254.21 | 23.01 | 0.09% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,497.94 | 35.99 | 0.34% |
| HKSE | 24,222.72 | 182.38 | 0.76% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 70,081.53 | 134.67 | 0.19% |
| NZX 50 Index | 13,705.69 | 6.67 | 0.05% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,752.80 | 66.40 | 0.76% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |